IN2014CN04067A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04067A
IN2014CN04067A IN4067CHN2014A IN2014CN04067A IN 2014CN04067 A IN2014CN04067 A IN 2014CN04067A IN 4067CHN2014 A IN4067CHN2014 A IN 4067CHN2014A IN 2014CN04067 A IN2014CN04067 A IN 2014CN04067A
Authority
IN
India
Prior art keywords
cancer
vegf
met
directed
treatment
Prior art date
Application number
Other languages
English (en)
Inventor
Dana T Aftab
Frauke Schimmoller
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of IN2014CN04067A publication Critical patent/IN2014CN04067A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
IN4067CHN2014 2011-11-08 2012-11-08 IN2014CN04067A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161557358P 2011-11-08 2011-11-08
PCT/US2012/064116 WO2013070890A1 (en) 2011-11-08 2012-11-08 Dual inhibitor of met and vegf for treating cancer

Publications (1)

Publication Number Publication Date
IN2014CN04067A true IN2014CN04067A (cg-RX-API-DMAC7.html) 2015-10-23

Family

ID=47179011

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4067CHN2014 IN2014CN04067A (cg-RX-API-DMAC7.html) 2011-11-08 2012-11-08

Country Status (15)

Country Link
US (1) US20140323522A1 (cg-RX-API-DMAC7.html)
EP (1) EP2776033A1 (cg-RX-API-DMAC7.html)
JP (2) JP2014532766A (cg-RX-API-DMAC7.html)
KR (1) KR20140088610A (cg-RX-API-DMAC7.html)
CN (1) CN104159585A (cg-RX-API-DMAC7.html)
AU (2) AU2012335737A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014011009A2 (cg-RX-API-DMAC7.html)
CA (1) CA2854336A1 (cg-RX-API-DMAC7.html)
EA (1) EA201490944A1 (cg-RX-API-DMAC7.html)
HK (1) HK1202062A1 (cg-RX-API-DMAC7.html)
IL (1) IL232421A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN04067A (cg-RX-API-DMAC7.html)
MX (1) MX2014005458A (cg-RX-API-DMAC7.html)
TW (2) TWI662962B (cg-RX-API-DMAC7.html)
WO (1) WO2013070890A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CN103402505A (zh) 2010-09-27 2013-11-20 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
KR102030447B1 (ko) 2011-02-10 2019-11-08 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
KR20140025496A (ko) 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
MX351133B (es) 2011-09-22 2017-10-03 Exelixis Inc Metodo para tratar osteoporosis.
IN2014CN02971A (cg-RX-API-DMAC7.html) 2011-10-20 2015-07-03 Exelixis Inc
JP2015515988A (ja) * 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
EP2970126B1 (en) 2013-03-15 2019-03-06 Exelixis, Inc. Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
WO2014165786A1 (en) 2013-04-04 2014-10-09 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
US9149471B2 (en) * 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis
AU2015218236B2 (en) 2014-02-14 2019-06-13 Exelixis, Inc. Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
WO2016019285A1 (en) 2014-07-31 2016-02-04 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
KR102634247B1 (ko) 2014-08-05 2024-02-05 엑셀리시스, 인코포레이티드 다발성 골수종을 치료하기 위한 약물 병용물
CN105503717A (zh) * 2014-09-24 2016-04-20 江苏奥赛康药业股份有限公司 一种苹果酸卡博替尼化合物及其药物组合物
CA3020749A1 (en) * 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CA3040788C (en) * 2016-10-18 2022-01-11 Beijing Konruns Pharmaceutical Co., Ltd. Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same
DK3630726T3 (da) 2017-05-26 2022-03-07 Exelixis Inc Krystallinske faste former af salte af n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropan-1,1-dicarboxamid, processer til fremstilling og fremgangsmåder til anvendelse
SG11202006921PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
EP3806858A4 (en) 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
CN120417903A (zh) 2023-01-31 2025-08-01 汉达癌症医药责任有限公司 改良的卡博替尼组合物及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP2392565B1 (en) 2003-09-26 2014-03-19 Exelixis, Inc. c-Met modulators and methods of use
WO2008083319A1 (en) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Solid state forms of enantiopure ilaprazole
UA108618C2 (uk) * 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
JP2013537918A (ja) * 2010-09-27 2013-10-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
CN103402505A (zh) * 2010-09-27 2013-11-20 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂

Also Published As

Publication number Publication date
TW201818937A (zh) 2018-06-01
MX2014005458A (es) 2015-04-16
JP2014532766A (ja) 2014-12-08
TW201322981A (zh) 2013-06-16
BR112014011009A2 (pt) 2017-06-06
EA201490944A1 (ru) 2014-10-30
US20140323522A1 (en) 2014-10-30
AU2017225103A1 (en) 2017-09-28
HK1202062A1 (en) 2015-09-18
WO2013070890A1 (en) 2013-05-16
EP2776033A1 (en) 2014-09-17
JP2018048154A (ja) 2018-03-29
TWI662962B (zh) 2019-06-21
KR20140088610A (ko) 2014-07-10
IL232421A0 (en) 2014-06-30
AU2012335737A1 (en) 2014-06-05
CN104159585A (zh) 2014-11-19
CA2854336A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
IN2014CN04067A (cg-RX-API-DMAC7.html)
MX2013003594A (es) Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis de osteoblasticas en los huesosl.
HK1207587A1 (en) A dual met - vegf modulator for treating osteolytic bone metastases
IL224370B (en) Combination treatment for prostate carcinoma
IL304337A (en) Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
IL232530A0 (en) Combined cancer treatment
SG10201508495VA (en) Combination treatment of cancer
BR112013024211A2 (pt) tratamento de tumores sólidos
MX2011011431A (es) Composicion para el tratamiento de cancer de prostata.
IL225689A0 (en) Cancer treatment/inhibition of metastasis
IL228430A0 (en) Cancer treatment
ZA201300762B (en) Novel combination therapy for the treatment of cancer
IN2014DN00254A (cg-RX-API-DMAC7.html)
MX2013006526A (es) Dosis de los derivados de arilsulfonamida.
HK1187832A (en) Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
HK1187831A (en) Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
GB201017316D0 (en) Treatment of cancer/inhibition of metastasis
GB201017356D0 (en) Combination treatment of cancer
GB201121791D0 (en) Combination treatment of cancer
GB201017354D0 (en) Treatment of cancer
JO3550B1 (ar) مركب لمعالجة سرطان البروستاتا
TH0901005197A (th) การบำบัดต้านการเจริญเติบโตของเส้นโลหิตสำหรับการรักษาของโรคมะเร็งเต้านม
GB201121783D0 (en) Treatment of cancer